Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Provectus Pharmaceuticals, an oncology and dermatology biopharmaceutical company, has added Mount Sinai School of Medicine as its second and final site for its expanded Phase II clinical trial of the company's lead dermatology agent PH-10 for atopic dermatitis.
Subscribe to our email newsletter
Mount Sinai School of Medicine has been added as a center for the Phase II study because of its reputation in dermatological research. It is anticipated that the timeline for the completion of the Phase II trial will remain approximately the same. Mount Sinai School of Medicine is also involved in the company’s Phase II trial of PH-10 for psoriasis.
Craig Dees, CEO of Provectus, said: “Opening the center at Mount Sinai fits very well with all of our Phase II programs in dermatology and oncology, as our centers include some of the most prestigious sites and thought leaders in their respective fields. Mount Sinai has already begun enrollment in the study and we look forward to the contributions of Dr Emer and his team.”